| Variables | Commercial Plans 15,599 (59.8%) | Medicare 2,568 (9.8%) | Medicaid 7,931 (30.4%) |
|---|---|---|---|
| Drug regimen, n (%) | |||
| SIM/SOF | 1,468 (9.4) | 314 (12.2) | 442 (5.6) |
| LDV/SOF | 11,095 (71.1) | 1,859 (72.4) | 4,734 (59.7) |
| OPrD | 1,773 (11.4) | 140 (5.5) | 677 (8.5) |
| SOF/VEL | 1,026 (6.6) | 120 (4.7) | 890 (11.2) |
| EBR/GZR | 192 (1.2) | 125 (4.9) | 1,044 (13.2) |
| GLE/PIB | 45 (0.3) | 10 (0.4) | 144 (1.8) |
| Male, n (%) | 9,588 (61.5) | 1,618 (63) | 4,589 (57.9) |
| Age, years, median (IQR) | 58 (53-61) | 67 (65-70) | 57 (51-60) |
| Year of cohort entry, n (%) | |||
| 2014 | 2,867 (18.4) | 530 (20.6) | 635 (8.0) |
| 2015 | 6,117 (39.2) | 1,008 (39.3) | 2,079 (26.2) |
| 2016 | 3,808 (24.4) | 675 (26.3) | 2,471 (31.2) |
| 2017 | 2,807 (18.0) | 355 (13.8) | 2,746 (34.6) |
| Urban, n (%)a | 14,062 (90.2) | 2,398 (93.4) | – |
| Full-time employment, n (%)a | 9,605 (61.6) | 391 (15.2) | – |
| Race, n (%)b | |||
| White | – | – | 3,724 (49.6) |
| Black | – | – | 2,580 (34.3) |
| Hispanic | – | – | 119 (1.6) |
| Other | – | – | 1,090 (14.5) |
| Charlson Comorbidity Index, mean (SD) | 1.6 (2.0) | 2.5 (2.5) | 2.5 (2.5) |
| Comorbities, n (%) | |||
| Cirrhosis | 2,686 (17.2) | 606 (23.6) | 2,218 (28.0) |
| Anemia | 1,132 (7.3) | 356 (13.9) | 894 (11.3) |
| Decompensated cirrhosis | 1,173 (7.5) | 234 (9.1) | 1,053 (13.3) |
| Diabetes | 2,750 (17.6) | 778 (30.3) | 1,781 (22.5) |
| HIV infection | 408 (2.6) | 35 (1.4) | 363 (4.6) |
| Drug abuse | 871 (5.6) | 77 (3.0) | 1,146 (14.5) |
| Alcohol abuse | 838 (5.4) | 96 (3.7) | 1,129 (14.2) |
| Past use of interferon, ribavirin, telaprevir, or boceprevir, n (%)c | 1,089 (7.0) | 178 (6.9) | 400 (5.0) |
| Interferon | 875 (5.6) | 166 (6.5) | 299 (3.8) |
| Ribavirin | 1,076 (6.9) | 172 (6.7) | 394 (5.0) |
| Telaprevir | 565 (3.6) | 94 (3.7) | 124 (1.6) |
| Boceprevir | 213 (1.4) | 45 (1.8) | 91 (1.2) |
| Number of physician visits, mean (SD) | 11.6 (11.2) | 15.8 (14.6) | 14.7 (16.4) |
| Number of ED visits, mean (SD) | 0.5 (1.2) | 0.5 (1.2) | 2 (3.6) |
| Number of hospitalizations, mean (SD) | 0.2 (0.7) | 0.2 (0.6) | 0.5 (1.1) |
aMissing values for Medicaid-covered patients (n = 7,931).
bMissing values for commercial plans and Medicare-covered patients (n = 18,585).
cUse in the year before cohort entry.
EBR/GZR = elbasvir/grazoprevir; ED = emergency department; GLE/PIB = glecaprevir/pibrentasvir; HIV = human immunodeficiency virus; IQR = interquartile range; LDV/SOF = ledipasvir/sofosbuvir; OPrD = ombitasvir/paritaprevir/ritonavir + dasabuvir; SD = standard deviation; SIM/SOF = simeprevir/sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir.